New Generation of Tissue-Targeted Nanoparticle Based In Vivo Transfection Kit for Animal Research Developed by Altogen Biosystems

Las Vegas, NV, October 02, 2015 --(PR.com)-- Researchers can now effectively deliver molecular targeted medicines into a myriad of tissues using nanotechnology. Altogen Biosystems has developed a new generation of highly efficient Nanoparticle-based In Vivo Transfection Kit that it exclusively manufactures. Nanoparticle technology can be utilized as carriers for nucleic acids such as DNA and RNA as well as small molecule-based drugs and proteins through a coating with biological polymers that form complexes with the negatively charged nucleic acids and condensed into nanoparticles. This binding and complex formation occurs within 30 minutes and can subsequently be administered in vivo via IV, IP, and IT administration routes.

Nanoparticles are used as carriers for nucleic acids and other novel cancer therapeutic molecules. The nanoparticles have an approximate size of 100 nm and are additionally coated with biodegradable polymers to allow loading of nucleic acids.

The complex with cargo nucleic acids form by ionic interaction of the negatively charged nucleic acid and the positively charged surface of the nanoparticle.

This kit is designed for preclinical research applications including oncology and cancer research. Furthermore, all Altogen Biosystems In Vivo Transfection Kits are capable of transfecting siRNA, miRNA, DNA and small proteins into various types of animal tissues including pancreatic, brain, kidney, lung, and tumor using systematic intravenous injection, intraperitoneal and direct intratumoral injection.

The Nanoparticle-based In Vivo Transfection developed by Altogen Biosystems has been functionally tested in mice and rats and manufactured under strict QC standards. The kit has multiple advantages for RNAi applications and compatible with siRNA complexing and administration to achieve sustained gene knockdown (gene silencing via in vivo mRNA knockdown) after a single injection. The kit includes pre-optimized in vivo protocols in order to streamline your research.

Read more about and order the commercially available Nanoparticle Based In Vivo Transfection Kit at http://www.altogen.com/nanoparticle-based-in-vivo-transfection-reagent.php.

As a leading provider of preclinical biology research products and services, Altogen Labs (www.altogenlabs.com) ensures quality of all Altogen® in vivo products and services.

Source: Altogen Biosystems, 848 Rainbow Blvd #823, Las Vegas, NV 89107. Tel: (702) 349-6103. Fax: (702) 989-0841. E-mail: techserv@altogen.com

Links:
Altogen Biosystems: www.altogen.com
Nanoparticle-based In Vivo Transfection Reagent:
http://www.altogen.com/nanoparticle-based-in-vivo-transfection-reagent.php
PEG-Liposome In Vivo Transfection Kit:
www.altogen.com/peg-liposome-based-in-vivo-transfection-reagent.php
Altogen In Vivo Transfection Reagents: www.altogen.com/mirna.php